These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35505173)

  • 21. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
    Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
    Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.
    Abdel-Maksoud MS; Ammar UM; Oh CH
    Bioorg Med Chem; 2019 May; 27(10):2041-2051. PubMed ID: 30955995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
    Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
    PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
    Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obstruction of BRAF
    Rothman JH; Surriga O; de Stanchina E; Vasudeva SD; Schwartz GK
    Cancer Gene Ther; 2017 Sep; 24(9):401-408. PubMed ID: 28937091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
    Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
    Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
    [No Abstract]   [Full Text] [Related]  

  • 29.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 30. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
    J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HI-511 overcomes melanoma drug resistance
    Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
    Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
    [No Abstract]   [Full Text] [Related]  

  • 32. Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study.
    Hunt HL; Goncalves BG; Biggs MA; Rico MI; Murray ME; Lebedenko CG; Banerjee IA
    Mol Divers; 2024 Dec; 28(6):3683-3711. PubMed ID: 38240950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
    Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
    Yang Y; Qin J; Liu H; Yao X
    J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.
    Zhao K; Zhou X; Ding M
    J Mol Graph Model; 2018 Jan; 79():59-64. PubMed ID: 29145034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF
    Porcelli L; Di Fonte R; Pierri CL; Fucci L; Saponaro C; Armenio A; Serratì S; Strippoli S; Fasano R; Volpicella M; Daprile R; Tommasi S; Ressa CM; Guida M; Azzariti A
    Pharmacol Res; 2022 Aug; 182():106323. PubMed ID: 35752358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of New Imidazo[2,1-
    Abdel-Maksoud MS; El-Gamal MI; Lee BS; Gamal El-Din MM; Jeon HR; Kwon D; Ammar UM; Mersal KI; Ali EMH; Lee KT; Yoo KH; Han DK; Lee JK; Kim G; Choi HS; Kwon YJ; Lee KH; Oh CH
    J Med Chem; 2021 May; 64(10):6877-6901. PubMed ID: 33999621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations.
    Moral-Sanz J; Fernandez-Rojo MA; Potriquet J; Mukhopadhyay P; Brust A; Wilhelm P; Smallwood TB; Clark RJ; Fry BG; Alewood PF; Waddell N; Miles JJ; Mulvenna JP; Ikonomopoulou MP
    Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33672955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.
    Kadioglu O; Saeed MEM; Greten HJ; Mayr K; Schrama D; Roos WP; Efferth T
    J Am Acad Dermatol; 2021 Apr; 84(4):1086-1089. PubMed ID: 32707252
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.